Video: Risk Management of Adventitious Agent Contamination in Biopharmaceutical Products - - BioPharm International

ADVERTISEMENT

Video: Risk Management of Adventitious Agent Contamination in Biopharmaceutical Products


Untitled Document

During this podcast, we will discuss the causes and implications of Adventitious Agent Contamination for pharmaceutical and biopharmaceutical manufacturers. We will discuss ways in which Lancaster Laboratories is helping manufacturers minimize the risk for this contamination to avoid production delays.

Presenter:
Jeri Ann Boose, Ph.D.
Director, Biopharmaceutical Services
Lancaster Laboratories

Katherine Bergmann, Ph.D.
Manager, Viral Safety and Viral Clearance Services
Lancaster Laboratories

Online Resources:
Register for the Live Web Conference
More Information

 

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here